+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 26 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating ASP5541, a new form of abiraterone acetate given by muscle injection, in men with advanced prostate cancer. The study compares ASP5541, with or without prednisoneprednisolone, to standard abiraterone acetate tablets plus prednisoneprednisolone. It aims to assess the safety and effectiveness of ASP5541 in men with metastatic hormone-sensitive and metastatic castration-resistant prostate cancer who have not previously received androgen receptor pathway inhibitors. Participants are assigned to one of three groups men with metastatic castration-resistant prostate cancer receive either ASP5541 plus prednisoneprednisolone or abiraterone acetate plus prednisoneprednisolone men with metastatic hormone-sensitive prostate cancer receive either ASP5541 alone or abiraterone acetate with prednisoneprednisolone and Japanese men with either cancer type receive ASP5541 with prednisoneprednisolone. ASP5541 is administered by injection every 12 weeks, prednisoneprednisolone is taken orally once or twice daily depending on cancer type, and abiraterone acetate is taken daily as tablets. All participants continue standard androgen deprivation therapy. During the study, participants will have regular clinic visits for health monitoring and safety checks, with some checking blood pressure weekly at home. Imaging scans and laboratory tests will assess cancer progression and treatment effects. Researchers will measure outcomes such as prostate-specific antigen levels, safety events, testosterone suppression, and cancer progression. The study includes long-term follow-up for up to 84 months and aims to provide detailed information on the safety and efficacy of ASP5541 compared to existing treatments.

Age: 18Years +MALEPhase 2
54 locations
P

Actively Recruiting

Researchers are evaluating HLX22 combined with trastuzumab and chemotherapy as a first-line treatment for patients with HER2-positive locally advanced or metastatic adenocarcinoma of the gastric or gastroesophageal junction. This phase 3, randomized, double-blind study compares this combination against trastuzumab plus chemotherapy with or without pembrolizumab. The trial aims to assess the efficacy and safety of adding HLX22 in this patient population. Participants will be randomly assigned in a 11 ratio to either the experimental group receiving HLX22 15 mgkg plus trastuzumab and chemotherapy XELOX with or without a placebo for pembrolizumab every three weeks, or the control group receiving placebo for HLX22 plus trastuzumab and chemotherapy XELOX with or without pembrolizumab also every three weeks. Treatment continues until clinical benefit is lost, intolerable side effects occur, death, withdrawal, or other protocol-specified reasons. Throughout the study, participants will have their disease progression monitored by an independent radiology review committee using RECIST v1.1 criteria for up to five years, along with overall survival and response rates. Safety will be regularly assessed by tracking adverse events. The study includes multiple assessments to evaluate treatment effects, and participants will be followed for long-term outcomes during the trial period.

Age: 18Years +All GendersPhase 3
208 locations
S

Actively Recruiting

Researchers are evaluating Risvutatug rezetecan Ris-Rez, a new medicine targeting specific proteins B7-H3 on cancer cells, in people with relapsed small cell lung cancer SCLC. The study compares Ris-Rez with the standard treatment topotecan to see if Ris-Rez can shrink tumors or make them disappear and if it helps participants live longer. It also examines the safety and side effects of both treatments to better understand their impact. Participants with relapsed SCLC will be randomly assigned to receive either Ris-Rez or topotecan. Both treatments will be administered according to standard protocols, with Ris-Rez provided as a biological therapy and topotecan as a drug treatment. The study is open-label, meaning both participants and researchers know which treatment is given. During the study, participants will be monitored through various assessments including survival time, tumor response, symptom changes, brain progression, and quality of life measures. Safety will be closely tracked through adverse event reports, laboratory tests, heart function evaluations, and immune response monitoring. The main outcome focuses on overall survival, with follow-up extending up to approximately 113 weeks to capture long-term effects and responses.

Age: 18Years +All GendersPhase 3
144 locations
P

Actively Recruiting

Researchers are evaluating the effectiveness and safety of Ifinatamab Deruxtecan I-DXd compared to the treatment chosen by a physician for people with relapsed small cell lung cancer SCLC. This Phase 3 study aims to see if I-DXd can help participants live longer than current treatments, while also examining other effects such as patient-reported outcomes, immune response, and the drugs behavior in the body. Participants will be randomly assigned to one of two groups. One group will receive I-DXd as an intravenous infusion at a dose of 12 mgkg every 21 days until the disease worsens, unacceptable side effects occur, or other stopping reasons arise. The other group will receive one of the standard treatments chosen by their doctortopotecan, lurbinectedin, or amrubicinaccording to local approved dosing guidelines and until treatment discontinuation criteria are met. During the study, participants will be closely monitored with regular imaging and assessments to track tumor response, disease progression, and quality of life using questionnaires. Safety events and immune responses will also be recorded. Pharmacokinetic samples will be collected at specified times to understand how I-DXd behaves in the body. Participants may remain in the study for up to approximately 3.7 years, allowing for long-term evaluation of outcomes and safety.

Age: 18Years +All GendersPhase 3
229 locations
E

Actively Recruiting

Researchers are evaluating the safety, effectiveness, and how the body processes a drug called YL201 when combined with atezolizumab in patients with advanced solid tumors, including extensive-stage small cell lung cancer ES-SCLC. This phase IbII, open-label study involves two parts focusing on dose levels and optimization to understand the best way to use YL201 alongside atezolizumab. The study aims to find doses that patients can tolerate and that show potential benefits. Participants receive YL201 through an intravenous infusion on the first day of each 21-day cycle, at doses of 1.2 mgkg, 1.6 mgkg, or 2.0 mgkg, combined with a fixed 1200 mg dose of atezolizumab given the same way and schedule. The study starts with a dose escalation phase, then moves to dose optimization with random assignment to one of the three dosing groups. Depending on results, the study continues with dose expansion using one or two selected dose levels. Treatment continues until the cancer progresses, unacceptable side effects occur, or the participant chooses to stop. During the study, participants undergo evaluations of side effects and dose-limiting toxicities over 21 days, with ongoing monitoring of adverse events until disease progression or death, lasting up to about six years. Secondary outcomes include response rates, duration of response, progression-free and overall survival, and detailed drug pharmacokinetics for up to three years. The long participation allows researchers to gather extensive safety and effectiveness data while closely monitoring participants throughout their treatment journey.

Age: 18Years +All GendersPhase 1Phase 2
38 locations
P

Actively Recruiting

Researchers are conducting a phase 1, multicenter, nonrandomized, open-label study to evaluate YL201 in patients with advanced solid tumors that have not responded to current treatments or lack standard therapy options. The study includes two parts Part 1 focuses on finding the maximum tolerated dose and recommended dose levels through dose escalation, while Part 2 enrolls patients with selected tumor types to further assess safety and efficacy of YL201. Participants will receive YL201 as an intravenous infusion once every three weeks in cycles. Some patients may receive YL201 alone at different dosages or in combination with atezolizumab during each 21-day cycle. Part 1 involves dose escalation cohorts to determine appropriate dosing, followed by Part 2 dose expansion cohorts to better define safety and evaluate treatment responses. Throughout the study, participants undergo tumor evaluations using RECIST criteria, laboratory tests, and safety monitoring to track adverse events, dose-limiting toxicities, and pharmacokinetics. For prostate cancer patients, prostate-specific antigen response and progression-free survival will be measured. The study lasts approximately 36 months, with ongoing assessments of tumor response, survival, and laboratory abnormalities conducted at regular intervals.

Age: 18Years +All GendersPhase 1Phase 2
45 locations
S

Actively Recruiting

Researchers are exploring new treatment options for people with advanced colorectal cancer that has spread or cannot be removed by surgery. This cancer type, affecting the colon or rectum, sometimes involves problems with the bodys DNA repair system called dMMR or a condition called MSI. These issues can cause cancer cells to rely on a protein called Werner helicase to survive. Blocking this protein might help stop cancer growth with less harm to healthy cells. This Phase 2 study evaluates a drug named VVD-133214 that blocks Werner helicase, combined with pembrolizumab, an immunotherapy drug approved to help the immune system attack cancer cells. Participants in this trial will receive oral VVD-133214 along with pembrolizumab given by intravenous infusion every three weeks. The study compares this combination to pembrolizumab alone to find the best dose of VVD-133214 and to assess whether the combination works better. Participants will receive VVD-133214 as long as it remains helpful without causing serious side effects, while pembrolizumab treatment will continue for up to two years. Participants may stop treatment at any time. During the trial, participants will have regular visits for tests, scans, and health check-ups to monitor how their cancer responds and to track any new or worsening medical problems. After stopping treatment, follow-up visits will occur 30 days after the last VVD-133214 dose and 100 days after the last pembrolizumab dose. Long-term follow-up visits will continue every 90 days as long as participants agree to remain in the study. The main outcome measured is the progression-free survival rate at six months, with safety and other response measures also monitored throughout up to about 36 months.

Age: 18Years +All GendersPhase 2
122 locations
E

Actively Recruiting

Researchers are evaluating treatments for people with advanced non-small cell lung cancer NSCLC that has spread or cannot be controlled by current therapies. This study focuses on patients whose cancer cells have specific changes called HER2 mutations, which cause abnormal cell growth. The main goal is to compare the effectiveness and safety of a new drug called sevabertinib against the standard treatment for this condition. Participants will be randomly assigned to one of two groups one group will take sevabertinib tablets twice daily, and the other will receive the current standard treatment, which includes pembrolizumab combined with platinum-based chemotherapy given by vein infusion every 21 days. Those on standard treatment may switch to sevabertinib if their cancer worsens. Treatment continues as long as participants benefit and do not have severe side effects. During the study, participants will undergo scans like CT, PET, MRI, or X-rays to monitor their cancer. Health assessments include blood and urine tests, heart checks using electrocardiograms and echocardiograms, pregnancy tests when needed, and evaluations of how participants feel and any medical problems they experience. The main outcome measured is how long participants live without their cancer progressing, with other outcomes including overall survival and response rates. The study lasts up to about 4 years, with ongoing monitoring for safety and patient well-being.

Age: 18Years +All GendersPhase 3
279 locations
O

Actively Recruiting

Researchers are evaluating the safety and effectiveness of BGB-43395 combined with letrozole compared to a choice of approved cyclin-dependent kinase 46 inhibitors abemaciclib, palbociclib, or ribociclib combined with letrozole in adults with advanced or metastatic hormone receptor positive HR and human epidermal growth factor receptor 2 negative HER2- breast cancer. The study focuses on patients who have not previously received systemic treatment for advanced or metastatic disease. This phase 3 trial aims to provide insight into treatment options for this patient group. Participants are randomly assigned to one of two groups one receiving BGB-43395 plus letrozole, and the other receiving an investigators choice of CDK46 inhibitor abemaciclib, palbociclib, or ribociclib plus letrozole. All medications are taken orally. The study compares these treatment combinations over a period lasting up to approximately 4 years for primary outcomes, with longer follow-up for secondary outcomes. During the trial, participants will be regularly monitored for disease progression, response to treatment, overall survival, and safety through various assessments. These include evaluations of progression-free survival by independent review, overall response rate, duration of response, clinical benefit rate, and adverse events. Quality of life measures and other clinical outcomes are also tracked. Participant involvement may last up to 11 years to capture long-term effects and safety.

Age: 18Years +All GendersPhase 3
241 locations
P

Actively Recruiting

Researchers are studying OATD-02, an oral drug, to see if it is safe and can help improve tumor responses to immunotherapy by increasing arginine levels or having its own anti-tumor effects. This study focuses on participants with advanced or metastatic colorectal, ovarian, renal, or pancreatic cancers who have already tried standard cancer treatments. The trial is a phase I, open-label, dose-escalation study using a Modified Bayesian Optimal Interval design to find the best dose with manageable side effects. Participants will receive OATD-02 as a single treatment, starting at a dose of 2.5 mg once daily. The dose may be increased based on tolerance and side effects, assessed by dose-limiting toxicities. The treatment period may last up to 6 months, with up to 30 patients enrolled plus replacements if needed. The study design helps guide dose adjustments to balance safety and potential effectiveness. During the trial, participants will be monitored for side effects and safety over 6 months, including adverse events and dose-limiting toxicities. Researchers will also measure how the drug moves through the body and its anti-tumor activity, including response rates and progression-free survival. Participants will have regular assessments to evaluate these outcomes and their overall health, with the study ending in March 2027.

Age: 18Years +All GendersPhase 1
3 locations

1-10 of 26

1